Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Wharton's jelly conditioned medium and extracellular vesicles versus triamcinolone for lichen planopilaris
IRCT20200127046282N29Phase 2Completed
- Sponsor
- Tehran University of Medical Sciences
- Start
- May 2023
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Cell Therapies, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, single-blind trial of triamcinolone and extracellular vesicles derived from Wharton's jelly mesenchymal stem cells in lichen planopilaris (LPP) (3 arms), sponsored by Tehran University of Medical Sciences. Primary endpoints: Response to treatment and Amount of hair loss. Started May 2023; status: completed.
02
Drugs
triamcinoloneextracellular vesicles derived from Wharton's jelly mesenchymal stem cells
03
Conditions
lichen planopilaris (LPP)
Beyond the preview
Go deeper on IRCT20200127046282N29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20200127046282N29.